To avoid hepatotoxicity, a preventive dose reduction of peg‐asparaginase is advisable in predisposing factors such as chronic liver diseases and BMI > 30, correlating them to patients' age and pre‐existing hepatic steatosis. This evidence concerns the gene PAEP and fatty liver disease.